Research programme: cytokine coated nanoparticle therapeutics - Atossa Therapeutics/Dana-Farber Cancer Institute
Latest Information Update: 29 Apr 2021
At a glance
- Originator Atossa Therapeutics; Dana-Farber Cancer Institute
- Class Antineoplastics; Cytokines; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer